

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>4</sup> :</b> C12P 21/00, C07H 17/00 C07K 15/04, A61K 39/395	<b>A1</b>	<b>(11) International Publication Number:</b> WO 88/ 06630 <b>(43) International Publication Date:</b> 7 September 1988 (07.09.88)
<b>(21) International Application Number:</b> PCT/US88/00716 <b>(22) International Filing Date:</b> 2 March 1988 (02.03.88)  <b>(31) Priority Application Number:</b> 021,046 <b>(32) Priority Date:</b> 2 March 1987 (02.03.87) <b>(33) Priority Country:</b> US  <b>(71) Applicant:</b> GENEX CORPORATION [US/US]; 16020 Industrial Drive, Gaithersburg, MD 20877 (US). <b>(72) Inventors:</b> LADNER, Robert, Charles ; 3827 Green Valley Road, Ijamsville, MD 27754 (US). GLICK, J., Leslie ; 10899 Deborah Drive, Potomac, MD 20854 (US). BIRD, Robert, E. ; 3903 Morrell Court, Kensington, MD 20895 (US).		<b>(74) Agents:</b> FOX, Samuel, L. et al.; Saidman, Sterne, Kessler & Goldstein, 1225 Connecticut Avenue, N.W., Suite 300, Washington, DC 20036 (US).  <b>(81) Designated States:</b> AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> METHOD FOR THE PREPARATION OF BINDING MOLECULES  <b>(57) Abstract</b> <p>This invention comprises a genetically engineered organism displaying the expression product of an inserted gene on its outer surface. In a preferred embodiment, a single chain antibody is displayed on the outer surface of the genetically engineered microorganism.</p>		

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

-1-

## **Method for the Preparation of Binding Molecules**

### **Background of the Invention**

#### **Field of the Invention**

The present invention relates to the production of genetically engineered organisms and methods of preparation of binding molecules.

#### **Description of the Background Art**

In vertebrates, antibody diversity arises from substitution of hypervariable loops into constant antibody frameworks. Each B-cell exhibits its own type of specificity on its surface. When an antigen binds to the surface antibody, the B-cell is stimulated to proliferate.

Monoclonal antibody production exploits this as follows: An animal is injected with a purified antigen. After several weeks, the spleen is removed from the animal and spleen cells are fused to myeloma cells. This produces hybridoma cells. These cells are plated and screened for binding to antigen. These cells can be grown in tissue culture and will produce quantities of a single antibody--a monoclonal antibody.

The gene for the antibody can be recovered and put into microorganisms. Genetic and protein engineering can be altered to obtain better binding, altered specificity,

-2-

different antigenic behavior than that of the original protein or gene product.

Single-chain antibodies (SCA) (copending U.S. Patent Application Serial Nos. 902,971 and 902,970, herein incorporated by reference) are protein molecules which retain the binding domain of antibodies but not the effector domains.

#### SUMMARY OF THE INVENTION

In the present invention, a genetically engineered organism is produced which displays on the outer surface of the organism the expression product of a gene which has been inserted.

In one embodiment of the invention, a SCA domain (SCAD) is displayed on the outside of a microorganism while the message for that particular SCA is inside that organism.

#### Description of the Drawings

Figure 1, flow chart for production of organisms containing binding molecules on surface.

Figure 2, displaying SCAD on surface.

Figure 3, making diverse population of displayed SCADs.

Figure 4, selecting new SCA specificity.

Figure 5, detecting known antigens.

Figure 6, lambda assembly.

Figure 7, inserting SCAD into V genes.

#### DESCRIPTION OF PREFERRED EMBODIMENTS

Any protein or antibody domain for which a gene can be isolated or constructed may be displayed on the outer surface of an organism into which the gene has been inserted. This is done by fusing the SCAD gene to the gene coding for a product which normally expresses on the surface of the organism; e.g., an envelope protein. The organism so

produced may be easily isolated from organisms which do not contain the desired gene and express the gene product. The organisms may also serve as a solid substrate for the gene product. Prior to the present invention, once an organism which contained a desired gene had been produced, the organisms had to be grown and assayed for the production of the gene product. Then, the gene product had to be isolated, purified, and only then was it possible to couple it to a solid substrate. In one embodiment, the organism itself containing the gene product on its outer surface is the solid substrate with the desired gene product already attached and may be used as such.

The present invention is depicted in general terms in the flow chart on Figure 1. One embodiment shown at step 1000 consists of producing organisms. In this embodiment, a microorganism displays a gene product such as a SCAD on the surface of the organism. The next step (step 1010) consists of generating, from the one SCAD displayed and encoded in the organism, a diverse population of SCADs by varying the DNA sequence encoding the SCAD by mutation techniques. The new diverse SCADs generated in step 1010 are displayed on the surface of the organism (step 1020) and organisms are selected based on the surface expressed SCAD which bind to given antigens (step 1030). The organisms selected in step 1030 may be used in assays for the given antigen or may be further selected according to the binding or enzymatic characteristics of the gene product expressed on the surface.

Once any SCAD has been displayed on the surface of a microorganism, a large population of different SCADs can be generated by in vivo DNA synthesis, step 1010, and each cell or virion can display its own SCAD specificity, step 1020. Antigen binding to the displayed SCAD can be used to select

those microorganisms harboring genes for SCADs which will bind antigen, step 1030. Once a strain of microorganisms is selected for antigen binding, it can be used as a sensitive assay for that antigen, step 1040. In step 1050, the ability to refine antigen binding is used to generate novel enzymes.

The steps needed to achieve the construction of a microorganism which displays SCAD are shown in the flow chart of Figure 2. In step 2000, a microorganism is selected. In step 2010, a gene within that organism is selected; the gene must be one coding for a protein which is displayed on the cell or virion surface. Preferably, the gene should not be essential to the organism. In step 2020, the gene for a SCAD to some known antigen is introduced into the selected gene, and in step 2030, this population of modified genes is put back into the organism. In step 2040 the genes are expressed, and in step 2050 the organisms are selected for binding to immobilized antigen. In step 2060, the gene is sequenced to determine which insertion was fruitful.

The steps needed to create a diverse population of SCADs displayed on the surface of a microorganism are illustrated in the flow chart on Figure 3. In step 3000, the Combining Determining Regions (CDRs) of the SCA are bounded by restriction sites. In step 3010, a large variety of DNA sequences are produced. Each sequence should begin with one of the restriction sequences and end with the corresponding restriction site. Between these sites should come any constant residues which are included to facilitate placement of restriction sites plus an integral number of triplets. The number of triplets can be varied within the bounds set by:

1. Analysis of sequences of natural antibodies with similar framework;
2. Computer modeling of the framework;
3. Trial and error.

In step 3020, these DNA sequences are inserted into the appropriate slots in the SCAD gene. In step 3030, these genes are reinserted into the organism and grown. The organism now contains a diversity of SCA specifications, each cell displaying its own particular SCAD. In step 3040, this population is passed over the inert support which will be used to support antigen. This step removes those organisms which bind to the inert support even without antigen.

In step 4000 in Figure 4, the antigen is attached to an inert support. In step 4010, the population of organisms prepared in steps 3000 to 3040 is passed over the supported antigen. Organisms not binding pass through. In step 4020, the organisms bound to the support are allowed to grow. In step 4030, colonies are found and sampled. In step 4040, the genes of several isolates are sequenced. In step 4050, the SCAD gene of selected organisms are mutagenized. In step 4060, step 4010 through 4050 are repeated with the mutagenized colonies. In step 4060, by washing more stringently, a SCA colony with maximal binding is obtained. Step 4060 can be repeated until suitable binding is obtained.

The present invention is also useful for the detection and quantification of known antigens. In step 5000 of Figure 5, a sample with unknown amount of an antigen is attached to an inert support. In step 5010, the strain of organism derived in step 4060 and displaying a SCAD against the antigen is passed over the inert support. In step 5020, the bound organisms are allowed to grow. In step 5030, points of growth are detected, the amount of growth quantitates the amount of antigen.

Enzymes, particularly degradative enzymes, work by stabilizing the transition state of a reaction. Chemical theory suggests the shape of the transition states of many reactions. For example, the carbonyl carbons of esters of


carboxylic acids are trigonal planar. The transition state for hydrolysis or transesterification is almost certainly tetrahedral. It has recently been demonstrated that a monoclonal antibody against a phosphate ester (which is tetrahedral) is also an esterase.

Monoclonal antibody technology has many shortcomings for this task:


1. Slow turnaround
2. Difficulty in refining antibody
3. Inappropriate for highly toxic chemicals
4. Inappropriate for metabolites

The method described above can be applied to produce such enzyme-like binding molecules. It will be limited only in the ability to invent antigens which resemble the transition states of reactions wished to catalyze.

For example, to catalyze the transesterification



one can raise a SCA against



Having now generally described the invention, the same may further be understood by reference to the following



expressly stated.

#### Example 1

The preferred embodiment utilizes the bacteriophage lambda. The gene V of lambda generates a protein which assembles to form the neck of lambda. First gene product V (gpV) forms hexameric annuli, then 32 of these annuli stack on the nose cone to form the neck (Figure 6). Finally, the neck joins the head which contains the DNA.

gpV is a protein of molecular weight 31K. Wild-type lambda have small protuberances on the outside of the neck annuli. Mutants have been isolated in which as much as 13K of gpV is absent. These mutants are viable, though temperature sensitive. The mutants are those wherein shortened gpV lack the protuberances on the neck annuli. Genetics indicates that the deletion is from the carboxy end of gene V.

SCAs made so far contain the four cysteine residues found in all  $V^H$  and  $V^L$  domains of natural antibodies. Natural antibodies are secreted and fold in the oxidizing environment of serum. The interior of cells is a reducing environment; thus, one would not expect disulfide bonds to form. The sulfhydryl groups of cysteine lie only 2.0 Å apart when a disulfide forms. If the disulfide is reduced, the sulfur atoms should lie 4.0 Å apart. Thus, reduced cysteines will greatly destabilize folding of a SCA. Therefore, to get proper folding of SCAD inside a cell, one mutates the SCAD gene to change all or some of the CYS's to SER, THR, ALA, or GLY. In one embodiment, the SCA is against bovine growth hormone (BGH).

The V gene of lambda is shown in Figure 7. Genetics indicates that the domain responsible for the warts on the neck lies in the 300 to 400 last base pairs to the right. One cuts the gene at some point in this region, preferably

200 bases from the right end. A random number of bases on either side, up to 200 bases is removed. The SCAD (antiBGH) is inserted and put back into a lysogenic strain of E. coli. In the preferred embodiment, the lambda contains a highly beneficial gene for the E. coli.

The E. coli is induced. The lambda progeny is passed over a support holding BGH. The E. coli is contacted with the support. The coli should be deficient in a way that the beneficial gene in the lambda will complement. For example the coli could be drug-sensitive and lambda will carry drug resistance. The corresponding antibiotic in the medium puts the coli under selective pressure so that only those cells infected by lambda will grow. Only those lambda which bound antigen and stuck to the support are available.

WE CLAIM:

1. An organism containing a recombinant gene wherein the product of said recombinant gene is presented on the outer surface of said organism, said product also comprising a single chain antibody domain (SCAD).
2. The organism of claim 1 wherein the product of said recombinant gene comprises a polypeptide which directs said SCAD to the surface of said organism.
3. A fusion polypeptide comprising a product normally appearing on the surface of an organism fused to a single chain antibody domain.
4. A method of preparing an organism containing a single chain binding molecule on the outer surface of said organism which comprises:
  - (1) isolating from an organism a first gene encoding for a cell surface protein;
  - (2) inserting a second gene which encodes a single chain antibody domain into said first gene to form a recombinant fusion gene; and
  - (3) transforming an organism with said recombinant fusion gene.

1/7

1000

*Develop microorganism which displays  
SCAD on its surface*

1010

*Generate diverse population of  
SCADs*

1020

*Display diverse SCADs on  
microorganism*

1030

*Select strain of microorganism  
which binds given antigen*

1040

*Assay for given antigen using  
selected strain*

1050

*Develop novel enzymes*

**FIG. 1**  
**SUBSTITUTE SHEET**

2/7

2000

*Select a microorganism*

2010

*Select gene for surface  
protein*

2020

*Select SCAD (Anti Known Antigen)*

2030

*Insert SCAD gene into surface  
gene*

2040

*Return surface gene to  
organism*

2050

*Select for binding antigen*

2060

*Sequence selected gene*

FIG. 2

SUBSTITUTE SHEET

3/7




FIG. 3

4/7

4000

*Attach antigen to inert support*

4010

*Pass population over support*

4020

*Grow organisms that bound antigen*

4030

*Detect colonies of organisms*

4040

*Isolate SCAD gene of colonies  
that bind*

4050

*Mutagenize SCADs & return  
to organism*


4060

*Repeat steps 4010 through  
4050 as needed*

FIG. 4

SUBSTITUTE SHEET

5/7



*FIG. 5*  
*Detecting Known Antigens*



6/7




FIG. 6

7/7




FIG. 7

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 88/00716

## I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) <sup>3</sup>

According to International Patent Classification (IPC) or to both National Classification and IPC

C12P 21/00, C07H 17/00, C07K 15/04, A61K 39/395

## II. FIELDS SEARCHED

Minimum Documentation Searched <sup>4</sup>

Classification System	Classification Symbols
US	435/68, 70, 172.3, 235, 948, 91, 530/387, 388, 424/85, 536/27

Documentation Searched other than Minimum Documentation  
to the Extent that such Documents are Included in the Fields Searched <sup>6</sup>

Computer Search CAS, BIOSIS, APS: Immunogloulin, clone 1, plasmid 1, surface, secrete, signal or leader, coat protein, viral vector, GPV protein

## III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>14</sup>

Category <sup>5</sup>	Citation of Document, <sup>16</sup> with Indication, where appropriate, of the relevant passages <sup>17</sup>	Relevant to Claim No. <sup>18</sup>
A	Science, Vol. 81, issued August, 1987, (Washington, D.C., U.S.A.), (R. HUBER) "Structural Basis for antigen-antibody Recognition". See entire document. pages 702-703.	1-4
Y	U.S.,A, 4,704,692, (LADNER) issued 03 November 1987. See the entire document.	1-4
Y	U.S.,A, 4,603, 112, (PAOLETTI ET AL) issued 29 July 1986. See columns 1-3 in particular and abstract.	1-4
Y	Biotechnology, Vol. 3, issued April 1985, (New York, New York, U.S.A.), (VALENZUELA ET AL) "Antigen Engineering in Yeast: Synthesis and Assembly of Hybrid Hepatitis B Surface Antigen-Herpes Simplex 1 gD Particles", pages 323-326.	1-4

<sup>5</sup> Special categories of cited documents: <sup>15</sup>

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search <sup>1</sup>

06 MAY 1988

International Searching Authority <sup>1</sup>

ISA/US

Date of Mailing of this International Search Report <sup>1</sup>

24 JUN 1988

Signature of Authorized Officer <sup>10</sup>

*Robin L. Teskin*  
ROBIN L. TESKIN

## III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, <sup>1</sup> with indication, where appropriate, of the relevant passages <sup>2</sup>	Relevant to Claim No <sup>3</sup>
------------	--	-----------------------------------

A	<u>Biotechnology</u> , Volume 4, issued April 1986, (New York, New York), (J. Van Brunt) "Protein Architecture: Designing from the Ground Up", see pages 277-283.	1-4
---	---	-----

Y	U.S.A., 4,593,002, (DULBECCO) issued 03 June 1986. See the entire document.	1-4
---	---	-----



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/033,244	12/27/2001	David Botstein	P2930R1C2	1015

7590 09/03/2004

Ginger R. Dreger  
Knobbe Martens Olson & Bear  
Suite 1150  
201 California Street  
San Francisco, CA 94111

EXAMINER

FREDMAN, JEFFREY NORMAN

ART UNIT	PAPER NUMBER
----------	--------------

1637

DATE MAILED: 09/03/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED  
JANUARY 12 1964  
U.S. DEPARTMENT OF AGRICULTURE

<b>Advisory Action</b>	Application No. 10/033,244	Applicant(s) BOTSTEIN ET AL.	
	Examiner Jeffrey Fredman	Art Unit 1637	

**--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

THE REPLY FILED 8/23/2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

**PERIOD FOR REPLY (check either a) or b))**

- a) ☐ The period for reply expires \_\_\_\_\_ months from the mailing date of the final rejection.
- b) ☒ The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

1. ☐ A Notice of Appeal was filed on \_\_\_\_\_. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.
2. ☐ The proposed amendment(s) will not be entered because:
- (a) ☐ they raise new issues that would require further consideration and/or search (see NOTE below);
  - (b) ☐ they raise the issue of new matter (see Note below);
  - (c) ☐ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
  - (d) ☐ they present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: \_\_\_\_\_

3. ☐ Applicant's reply has overcome the following rejection(s): \_\_\_\_\_.
4. ☐ Newly proposed or amended claim(s) \_\_\_\_\_ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
5. ☒ The a) ☐ affidavit, b) ☐ exhibit, or c) ☒ request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.
6. ☐ The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.
7. ☒ For purposes of Appeal, the proposed amendment(s) a) ☐ will not be entered or b) ☒ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.

The status of the claim(s) is (or will be) as follows:

Claim(s) allowed: \_\_\_\_\_.

Claim(s) objected to: \_\_\_\_\_.


Claim(s) rejected: 22-27.

Claim(s) withdrawn from consideration: \_\_\_\_\_.

8. ☐ The drawing correction filed on \_\_\_\_\_ is a) ☐ approved or b) ☐ disapproved by the Examiner.

9. ☒ Note the attached Information Disclosure Statement(s) (PTO-1449) Paper No(s). 4/21/03 + 4/29/03

10. ☐ Other: \_\_\_\_\_

  
 Jeffrey Fredman  
 Primary Examiner  
 Art Unit 1637

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
GNE.2930R1C2APPLICATION NO.  
10/033,244INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Botstein, et al.FILING DATE  
December 27, 2001GROUP  
1656RECEIVED  
APR 2 2 2003  
TECH CENTER 1600/2000

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
L	1	5,831,058	11/03/98	Fujiwara et al.		

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
2	WO 98 45437	10/15/98	PCT				
3	WO 00/04140	01/27/00	PCT				
4	WO 00 58472	10/05/00	PCT				
5	WO 01/29221	04/28/01	PCT				
6	WO 01 02568	01/11/01	PCT				

EXAMINER  
INITIAL

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

7	Database EMBL 'Online! Entry HSA24389, 08/14/96, Hillier, L. et al., "ze74b01.r1 Soares_fetal heart NbHH19W Homo sapiens cDNA clone IMAGE: 364681 5', mRNA sequence." Database accession no. AA024389 XP002230500
8	Database EMBL 'Online! Entry HSA25266, 08/14/96, Hillier, L. et al., "ze74b01.s1 Soares_fetal heart NbHH19W Homo sapiens cDNA clone IMAGE:364681 3', mRNA sequence." Database accession no. AA025266 XP002230501
9	Database EMBL [Online] md78c02.r1 Soares mouse embryo NbME1cDNA clone (06/22/96) Marra et al., "The WashU-HHMI Mouse EST Project" Database accession no. MM96732 XP002232923
10	Database EBI 'Online! (08/19/98) Strausberg R. "qa12e07.x1 NCI_CGAP_Bm23 Homo sapiens cDNA clone IMAGE:1686564 3' similar to contains TAR1.b2 MSR1 repetitive element; mRNA sequence." Database accession no. AI088845 XP002226252
11	Database EMBL [Online] (01/11/99) Hillier, L. et al. "ao87d07.x1 Schiller meningioma Homo sapiens cDNA clone IMAGE:1952845 3' similar to contains element TAR1 repetitive element; mRNA sequence." Database accession no. AI366107 XP002230801
12	Database EMBL [Online] (01/13/99) Strausberg R. "qz48e01.x1 NCI-CGAP-Kid11 Homo sapiens cDNA clone IMAGE:2030136 3', mRNA sequence." Database accession no. AI373244 XP002230802
13	Klein, et al. Selection for genes encoding secreted proteins and receptors, Proc. Natl. Acad. Sci. USA 93:7108-7113 (1996)
14	Tashiro, et al., Signal sequence trap: a cloning strategy for secreted proteins and type 1 membrane proteins, Science 261:600-603 (1993)


S:\DOCS\SKT\SKT-3493.DOC  
040803

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.





FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
GNE.2930R1 C2APPLICATION NO.  
10/033,244INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Botstein, et al.

MAY 01 2003

FILING DATE  
December 27, 2001GROUP  
1856

TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>h</i>	1	WO 00/04135	01/27/00	PCT				
<i>h</i>	2	DE 188 18 620	10/28/99	Germany				

EXAMINER  
INITIAL

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)


<i>h</i>	3	Database EMBL 'Online' (1997-10-31) Strausberg, R.: "np74e04.s1 NCI_CGAP_Br2 Homo sapiens cDNA clone IMAGE: 1132062 3' Database accession no. AA 632131
	4	Fransen, et al., Identification of peroxisomal proteins by using M13 phage protein VI phage display: molecular evidence that mammalian peroxisomes contain a 2,4-dienoyl-CoA reductase, Biochem. J. 348:561-568 (1999)
	5	Comparison between Accession No. AAY87109 and SEQ ID NO: 23
	6	Comparison between Accession No. AAY87196 and SEQ ID NO: 23
	7	Comparison between Accession No. AA025266 and SEQ ID NO: 8
	8	Comparison between Accession No. AA024389 and SEQ ID NO: 8
	9	Comparison between Accession No. AX118905 and SEQ ID NO: 8
	10	Comparison between Accession No. CAC38526.1 and SEQ ID NO: 8
	11	Comparison between Accession No. AX070106 and SEQ ID NO: 6
<i>h</i>	12	Comparison between Accession No. AAB40784 and SEQ ID NO: 6
<i>h</i>	13	Comparison between Accession No. AAC74993 and SEQ ID NO: 6

EXAMINER

DATE CONSIDERED

9/1/01

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 608; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

 FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. GNE.2830R1C2	APPLICATION NO. 10/033,244
	APPLICANT Botslein, et al.	
	FILING DATE December 27, 2001	GROUP 1656

RECEIVED

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
14	Comparison between Accession No. AI373244 and SEQ ID NO: 6
15	Comparison between Accession No. AI366107 and SEQ ID NO: 6
16	Comparison between Accession No. AR052531 and SEQ ID NO: 12
17	Comparison between Accession No. W63967 and SEQ ID NO: 12
18	Comparison between Accession No. AAZ98060 and SEQ ID NO: 23
19	Comparison between Accession No. AI08845 and SEQ ID NO: 23
20	Comparison between Accession No. AAV88653 and SEQ ID NO: 23

S:\DOCS\SKT\SKT-3634.DOC  
042403

EXAMINER	DATE CONSIDERED
<i>m</i>	9/1/07

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 608; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**